Summary
Resistance training (Strength training) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Sarcopenia. ClinicalTrials.gov lists 8 registered trials linking Resistance training (Strength training) to Sarcopenia: 1 is currently recruiting; 3 are active or not yet recruiting; 1 has completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT05194397). The largest enrolment is 241 participants (NCT05691166). Registration activity spans 2016 to 2026. No published literature item is linked to Resistance training (Strength training) and Sarcopenia in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Sarcopenia ranks 82 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 21.0 (trials 16.0, literature 0.0, tier 5, approved bonus 0.0) |
| Registered trials | 8 total: 1 recruiting, 3 active / not yet recruiting, 1 completed, 3 other |
| Linked publications | 0 |
| Agent type | Behavioural (Lifestyle) |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Reversing decline in aging muscles: expected trends, impacts and remedies · Halma M, Marik P, Varon J, Tuszynski J · 2025 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05194397 | Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors 2023 | recruiting | Phase 2 | 80 |
| NCT05691166 | Reducing Falls With Progressive Resistance Training for the Oldest Old Adults With Sarcopenia 2023 | active, not recruiting | Not applicable | 241 |
| NCT05497687 | Strength-building Lifestyle-integrated Intervention 2022 | completed | Not applicable | 40 |
| NCT07601321 | BCW-Based Resistance Training for Community-Dwelling Sarcopenia Patients 2026 | not yet recruiting | Not applicable | 100 |
| NCT06480643 | Effect of Exercise Type on Muscle Quality in Patients With OA, SARC and RA: an Explorative Study 2024 | not yet recruiting | Not applicable | 69 |
| NCT03266575 | Pulmonary Rehabilitation in End-Stage Liver Disease 2018 | terminated | Not applicable | 4 |
| NCT05778136 | Lung Cancer, Exercise and Force Development 2023 | status unknown | Not applicable | 20 |
| NCT02873676 | Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia 2016 | status unknown | Not applicable | 200 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: Reversing decline in aging muscles: expected trends, impacts and remedies · Halma M, Marik P, Varon J, Tuszynski J · 2025.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Resistance training (Strength training) approved for Sarcopenia?
Resistance training (Strength training) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Sarcopenia. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Resistance training (Strength training) in clinical trials for Sarcopenia?
ClinicalTrials.gov lists 8 registered trials linking Resistance training (Strength training) to Sarcopenia: 1 is currently recruiting; 3 are active or not yet recruiting; 1 has completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT05194397). The largest enrolment is 241 participants (NCT05691166). Registration activity spans 2016 to 2026.
What does the evidence show for Resistance training (Strength training) in Sarcopenia?
Resistance training (Strength training) has 1 completed registered trial for Sarcopenia but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.